Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 180, Issue 1-2, Pages 117-125Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2006.07.010
Keywords
substance P; neurokinin; neuropeptide; EAE; SR140333; MS
Categories
Funding
- NINDS NIH HHS [R01-NS 37570 01A2] Funding Source: Medline
Ask authors/readers for more resources
Substance P (SP) is a modulatory, pro-inflammatory neuropeptide. We investigated the role of the SP receptor, neurokinin-1 (NK-1), in EAE. Our data show that in the chronic phase, mice lacking NK-1 have improved mobility and decreased numbers of LFA-1 high CD4+ T cells and MOG-specific, IFN-gamma producing CD4+ T cells. SR140333, an NK-1 antagonist, administered alone during the chronic phase of EAE was not sufficient to ameliorate symptoms. These results indicate that SP, through NK-1, contributes to maintenance of CNS inflammation, and combining NK-1 antagonists with conventional anti-inflammatory treatments may enhance the success of treatments for diseases like multiple sclerosis. (c) 2006 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available